ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 508

Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study

José R. Azpiri-López1, Dionicio A. Galarza-Delgado2, Iris J. Colunga-Pedraza3, Jose A. Davila-Jimenez4, Estefania E. Abundis-Marquez4, Andres H. Guillen-Lozoya4, Francisco J. Torres-Quintanilla4, Aldo Valdovinos-Bañuelos4, Ray Ramos-Cázares4, Raymundo Vera-Pineda4, Jesus A. Cardenas-de la Garza4, Rosa I. Arvizu-Rivera4 and Adrián Martínez-Moreno4, 1Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, 2Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 3Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 4Hospital Universitario, UANL, Monterrey, Mexico

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Cardiovascular disease, Comorbidity, Heart disease, prevention and rheumatoid arthritis (RA)

Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved ejection fraction (HFpEF). Elevated left atrial pressure (LAP) may not only be a pathophysiologic substrate of symptoms in patients with HFpEF, it may also be direct prognostic markers.(1) Several studies have emphasized the importance of left atrial function in RA-patients. (2) Objective: to compare the LAP and diastolic left ventricle (LV) filling patterns between RA-patients and controls.

Methods:

A case-control study with RA patients aged 40 to 75 years that fulfilled the 2010 ACR/EULAR criteria and matching controls were included. Exclusion criteria: poor acoustic window, prior atherosclerotic cardiovascular (CV) disease and overlap syndromes. Patients were matched using age, sex and CV comorbidities. Transthoracic echocardiogram was performed by a board-certified cardiologist, and reviewed by two cardiologists. LAP was estimated using the Nagueh-formula [1.24 * (E/E’) + 1.9] and ASE’s guidelines were used to define elevated LAP and diastolic LV filling patterns.

Results:

A total of 80 RA-patients and 54 matched controls were included. Demographic and clinical characteristics are shown in Table 1. As shown in Table 2, the mean LAP was not significantly higher in RA-patients than controls (12.9 ± 3.6 vs 12.2 ± 2.5, P=0.18). The difference between elevated LAP prevalence was not significant among both groups (8.8% vs 5.6%, P=0.49). Abnormal diastolic LV filling pattern was more prevalent in RA-patients compared to controls. LAP showed null correlation with disease duration (r= 0.06 P= 0.64) and DAS 28-CRP (r=0.01 P=0.93).

Conclusion:

Left atrial pressure values were not different in Hispanic RA-patients evaluated when compared to controls and did not correlate with disease activity and duration. RA-patients had abnormal relaxation more frequently than controls.

  1. Hasenfuss G, et al. Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure Trial. J Card Fail. 2015;21(7):594–600.
  2. Maloberti A, et al. Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in RA. High Blood Press Cardiovasc Prev. 2018;25(1):97–104.

Table 1. Demographic and Clinical characteristics

RA

Control

P

(n=80)

(n=54)

Age, mean ± SD

55.3 ± 8.6

53.5 ± 6.3

0.182 (NS)

Women, n (%)

78 (97.5)

49 (90.7)

0.085 (NS)

Disease duration, mean ± SD

10.5 ± 8.5

–

–

DAS 28-CRP, mean ± SD

3.3 ± 1.31

–

–

DM type 2, n (%)

7 (8.8)

7 (13)

0.434 (NS)

Hypertension, n (%)

28 (35)

11 (20.4)

0.067 (NS)

Smoking, n (%)

6 (7.5)

6 (11.1)

0.473 (NS)

DAS 28-CRP – DAS 28 using C reactive protein, DM type 2 – Diabetes mellitus type 2, NS – Non-significant

Table 2. Echocardiographic findings

RA

Control

P

(n=80)

(n=54)

LAP (mmHg), mean ± SD

12.9 ± 3.6

12.2 ± 2.5

0.178 (NS)

Elevated LAP, n (%)

7 (8.8)

3 (5.6)

0.490 (NS)

E/E’, mean ± SD

8.88 ± 2.87

8.3 ± 2.06

0.206 (NS)

E/A, mean ± SD

1.05 ± 0.29

1.06 ± 0.32

0.855 (NS)

Diastolic LV filling pattern

Normal, n (%)

66 (82.5)

51 (94.4)

0.042

Impaired relaxation, n (%)

10 (12.5)

2 (3.7)

0.08 (NS)

Pseudonormal, n (%)

4 (5)

1 (1.9)

0.346 (NS)

Restrictive, n (%)

0 (0)

0 (0)

NS

LAP – Left atrial pressure, LV – Left ventricle, NS – Non-significant


Disclosure: J. R. Azpiri-López, None; D. A. Galarza-Delgado, None; I. J. Colunga-Pedraza, None; J. A. Davila-Jimenez, None; E. E. Abundis-Marquez, None; A. H. Guillen-Lozoya, None; F. J. Torres-Quintanilla, None; A. Valdovinos-Bañuelos, None; R. Ramos-Cázares, None; R. Vera-Pineda, None; J. A. Cardenas-de la Garza, None; R. I. Arvizu-Rivera, None; A. Martínez-Moreno, None.

To cite this abstract in AMA style:

Azpiri-López JR, Galarza-Delgado DA, Colunga-Pedraza IJ, Davila-Jimenez JA, Abundis-Marquez EE, Guillen-Lozoya AH, Torres-Quintanilla FJ, Valdovinos-Bañuelos A, Ramos-Cázares R, Vera-Pineda R, Cardenas-de la Garza JA, Arvizu-Rivera RI, Martínez-Moreno A. Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/non-invasive-evaluation-of-left-atrial-pressure-in-hispanic-patients-with-rheumatoid-arthritis-a-case-control-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-invasive-evaluation-of-left-atrial-pressure-in-hispanic-patients-with-rheumatoid-arthritis-a-case-control-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology